How a Nobel Prize Winning Scientist Dr. Shinya Yamanaka Discovered a way to Slow Cellular Aging and Extend Longevity

Aging is the greatest risk factor for most chronic diseases, including cardiovascular disease, cancer, diabetes, and neurodegenerative disorders. Traditionally, medicine has focused on treating each disease individually. However, growing evidence suggests that targeting the underlying biological mechanisms of aging may delay or prevent multiple diseases simultaneously (López-Otín, C. et. al., 2023).

One of the most important breakthroughs in this area came from the discovery that cellular identity is not fixed. Takahashi and Yamanaka showed that introducing four specific transcription factors into adult fibroblasts could revert them to a pluripotent, embryonic-like state (Takahashi and Yamanaka, 2006). This discovery demonstrated that aging and cellular specialization are, at least in part, reversible processes controlled by gene regulation and epigenetic mechanisms.

Over the past decade, scientists have learned that full reprogramming is not necessary to obtain rejuvenation benefits. Short or cyclic exposure to these factors known as partial reprogramming can reverse aging markers while preserving cell identity (Ocampo et al., 2016). This finding has created a new field focused on restoring youthful cellular function rather than merely slowing aging.

Yamanaka factors are transcriptional regulators originally identified for their ability to induce pluripotency, meaning they can return a mature cell to a youthful, stem-cell-like state. Oct4 serves as a master regulator by activating genes that maintain pluripotency; Sox2 partners with Oct3/4 to preserve the self-renewing capacity of stem cells; Klf4 regulates cellular metabolism, proliferation, and stress resistance; and c-Myc enhances gene activation and chromatin remodeling, making the genome more accessible for large-scale changes (Takahashi and Yamanaka, 2006).

The relevance of these factors to aging lies in the fact that many aspects of aging are tightly connected to epigenetic drift. Over time, the molecular marks that guide which genes are active or silent become disorganized. The result is a gradual decline in cellular function, reduced tissue repair, increased inflammation, and the accumulation of damaged or senescent cells. By resetting these epigenetic marks, Yamanaka factors allow cells to recover youthful patterns of gene expression. Importantly, when used briefly or in a controlled manner, a process known as partial reprogramming allows cells to maintain their identity while reversing many signs of aging.

Aging involves several interconnected processes often referred to as the “hallmarks of aging,” including genomic instability, mitochondrial dysfunction, cellular senescence, and stem cell exhaustion (López-Otín, C. et. al., 2023). Yamanaka factors appear to influence many of these pathways simultaneously.

One of the most important effects is the reversal of epigenetic aging. Experiments have demonstrated that cells exposed to partial reprogramming regain youthful DNA methylation patterns and gene expression profiles (Sarkar et al., 2020). The development of DNA methylation–based aging clocks, first established by Horvath, demonstrated that epigenetic signatures are strongly correlated with biological age (Horvath, 2013). Continued refinement of these biomarkers has improved the accuracy of biological age assessment, with second- and third-generation epigenetic clocks, including GrimAge and DunedinPACE, enabling more precise quantification of age-related changes and rejuvenation effects (Levine et al., 2018; Belsky et. al., 2020) . Consistent with these advances, multiple studies report that transient expression of Yamanaka factors can significantly reduce DNA methylation age in human cells, providing quantitative evidence of biological rejuvenation (Lu et al., 2020; Sarkar et al., 2020).

Cellular senescence is another key feature of aging. Senescent cells accumulate in tissues and release inflammatory molecules collectively called the senescence-associated secretory phenotype, or SASP, which contributes to chronic inflammation and tissue damage. Studies have shown that partial reprogramming reduces markers of senescence and improves tissue regeneration (Ocampo et al., 2016).

Mitochondrial decline is also central to aging. Older cells produce less energy and more reactive oxygen species, leading to oxidative damage. Reprogramming has been shown to restore mitochondrial metabolism and improve cellular bioenergetics, helping cells function more like younger counterparts (Lapasset et al., 2011).

Finally, stem cell exhaustion contributes to reduced tissue repair in aging organisms. Partial reprogramming has been shown to restore regenerative capacity in several tissues, including muscle and nervous tissue (Lu et al., 2020).

A series of groundbreaking studies over the past decade has demonstrated the rejuvenating potential of Yamanaka factors in living organisms. One of the most influential was conducted by Dr. Ocampo and colleagues in 2016, showing that mice with a premature aging disorder benefited from short, cyclic exposure to Yamanaka factors (Ocampo et al., 2016). The treatment improved tissue health, reduced inflammation, enhanced organ function, and significantly extended lifespan without causing loss of cell identity.

Another landmark study was published by Lu and colleagues in 2020 from Harvard University, demonstrating that Yamanaka factors could restore vision in old mice with optic nerve damage (Lu et al., 2020). Remarkably, retinal cells regained youthful epigenetic patterns and repaired damaged nerve fibers, showing that even highly specialized tissues can undergo rejuvenation. Additional studies in various mammalian tissues and human fibroblasts have confirmed similar findings, including restoration of youthful gene expression, improved mitochondrial performance, and reversal of cellular aging markers (Sarkar et al., 2020).

Recent advances between 2022 and 2024 have strengthened the concept of partial cellular reprogramming as a strategy for biological rejuvenation. Several independent studies have demonstrated that transient expression of OSK (Oct4, Sox2, and Klf4), excluding c-Myc, can reverse age-associated molecular hallmarks without inducing full pluripotency or tumorigenesis (Ocampo et al., 2016; Lu et al., 2020; Browder et al., 2022; Sarkar et al., 2023).

Importantly, omission of c-Myc, a well-established oncogene, appears to reduce the risk of teratoma formation and uncontrolled dedifferentiation. Teratomas arise when pluripotent stem cells or germ cells differentiate in an unregulated manner, generating heterogeneous tissues such as hair, muscle, bone, and teeth; these tumors are typically congenital and originate from misdirected primordial germ cells, most commonly in the ovaries, testes, or sacrococcygeal region (Thomson et al., 1998; Damjanov, 2009).

In aged murine models, cyclic or transient OSK expression has been shown to improve tissue repair capacity, restore youthful gene expression profiles, reduce epigenetic age as measured by DNA methylation clocks, and enhance metabolic resilience without loss of cellular identity (Lu et al., 2020; Browder et al., 2022). Collectively, these findings suggest that partial reprogramming strategies that exclude c-Myc may mitigate oncogenic risk while preserving the rejuvenative benefits associated with Yamanaka factor mediated epigenetic remodeling.

While Yamanaka factor-based reprogramming represents one of the most powerful approaches to reversing cellular aging, it currently involves sophisticated genetic or biochemical techniques that are not yet feasible for widespread public use. In contrast, a wide range of dietary supplements exhibit biological activities that overlap with or support pathways involved in cellular rejuvenation. Compounds such as fisetin, quercetin, curcumin, resveratrol, NMN, alpha-ketoglutarate, sulforaphane, and various botanical polyphenols have been shown to influence gene expression, enhance antioxidant defenses, improve mitochondrial health, or reduce cellular senescence. These mechanisms complement the rejuvenation driven by Yamanaka factors by creating a cellular environment that is less burdened by inflammation and oxidative stress. For example, senolytic supplements like fisetin help clear senescent cells, thereby reducing the inflammatory signals that can interfere with reprogramming-mediated rejuvenation. NAD⁺ boosters such as NMN support mitochondrial energy production, a process that becomes increasingly fragile during aging and during partial reprogramming (Yousefzadeh et al., 2018). Meanwhile, epigenetic regulators such as sulforaphane and resveratrol activate protective pathways including NRF2, AMPK, and sirtuins, which stabilize the epigenome and may help maintain youthful cellular states (Baur et al., 2006; Kensler et al., 2013). Alpha-ketoglutarate supplementation has been shown to extend lifespan and reduce frailty in mice, partly through epigenetic and metabolic effects (Asadi Shahmirzadi et al., 2020). Although supplements cannot induce reprogramming on their own, they may act synergistically with future Yamanaka factor based therapies by supporting healthy cellular function and enhancing resilience to age-related stressors. Together, these approaches suggest a future in which optimized nutrition, targeted supplementation, and controlled reprogramming strategies form a unified framework for promoting healthy aging and longevity.

The potential applications of the Yamanaka factor–based interventions for human health are extensive. In regenerative medicine, partial reprogramming could rejuvenate tissues that deteriorate with age, including muscles, skin, heart, and liver. This could improve wound healing, recovery from injury, and resistance to frailty in older adults. In the nervous system, partial reprogramming may one day repair age-related neurodegeneration, offering hope for conditions such as Alzheimer’s disease, Parkinson’s disease, and glaucoma.

Immune system aging is another key target. Because Yamanaka factors can rejuvenate hematopoietic stem cells, reprogramming-based therapies might restore robust immune function, reducing vulnerability to infections and cancer. Additionally, by reversing fundamental aging mechanisms such as epigenetic drift and mitochondrial dysfunction, this technology may help maintain metabolic balance, tissue repair, and systemic health well into advanced age. While supplements and lifestyle interventions provide accessible tools to help delay aging, Yamanaka factor–based therapies represent the possibility of actively reversing it.

Despite their promise, Yamanaka factor–based therapies present challenges that must be resolved before clinical use. Full reprogramming risks erasing cell identity and could trigger uncontrolled cell growth, leading to tumors. As a result, scientists are developing strategies to tightly regulate the timing, dose, and tissue specificity of reprogramming. Delivery methods also present challenges, as viral vectors pose integration risks, while non-viral approaches such as mRNA delivery or small-molecule substitutes remain under development.

Ethical considerations include questions about access, long-term societal effects, and potential misuse. If longevity-enhancing therapies become available, equitable distribution will be essential to prevent deepening health disparities. At the same time, cultural, economic, and regulatory implications must be explored.

Innovations in this field are advancing rapidly. Researchers are experimenting with replacing Yamanaka factors with small molecules, which may one day enable safe and reversible rejuvenation without altering the genome. Tissue-specific reprogramming, potentially activated only in response to cellular damage or aging signals, is another exciting direction. Several international biotechnology companies including Altos Labs, Life Biosciences, Retro Biosciences, and Calico are dedicating significant resources to developing reprogramming-based therapies. Many scientists believe that clinical trials involving partial reprogramming could begin within the next decade, initially targeting specific tissues such as the eye or muscle. 

A major advance supporting these future applications has been the development of small-molecule reprogramming strategies. In 2023, researchers demonstrated that human somatic cells can be reprogrammed using defined cocktails of small molecules without introducing exogenous genetic factors. This chemical reprogramming approach functions by modulating signaling pathways, chromatin architecture, and cellular metabolism to alter cell identity through pharmacological means. By avoiding viral vectors and transgene integration, this method may substantially reduce risks associated with gene therapy, including insertional mutagenesis and persistent oncogene expression. Consequently, small-molecule reprogramming is increasingly regarded as a promising pathway toward safer and more clinically viable rejuvenation and regenerative therapies (Guan et al., 2023).

The discovery of Yamanaka factors fundamentally transformed modern biology by demonstrating that cellular aging is reversible. Partial reprogramming has already shown the ability to reverse multiple hallmarks of aging, including mitochondrial decline, epigenetic drift, and cellular senescence. Although safety concerns and technical limitations remain, the potential for these factors to redefine aging medicine is immense. Combined with nutritional strategies and supplements that support cellular health, Yamanaka factor based interventions may ultimately pave the way toward a future in which aging itself becomes a treatable condition and one’s healthy lifespan can be substantially extended.

1. Asadi Shahmirzadi, A. et al. (2020). Alpha-ketoglutarate supplementation extends lifespan and compresses morbidity in mice. Cell Metabolism.

2. Baur, J. A. et al. (2006). Resveratrol improves health and survival of mice on a high-calorie diet. Nature.

3. Belsky, D. W., Caspi, A., Arseneault, L., et. al. (2020). Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm. eLife

4. Browder, K. C., Reddy, P., Yamamoto, M. et.al. (2022). In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nature Aging

5. Damjanov, I. (2009). Teratoma. In Diagnostic pathology and molecular genetics of the germ cell tumors (2nd ed.). Springer.

6. Guan, J., Wang, G., Wang, J. et.al., (2022). Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature

7. Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biology.

8. Kensler, T. W. et al. (2013). KEAP1–NRF2 signaling: a target for cancer prevention. Annual Review of Pharmacology and Toxicology.

9. Lapasset, L. et al. (2011). Rejuvenating senescent cells by reprogramming. Genes & Development.

10. Levine, M. E., Lu, A. T., Quach, A., Chen, B. H. et al., (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging

11. López-Otín, C. et. al. (2023). Hallmarks of aging: An expanding universe. Cell.

12. Lu, Y. et al. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature.

13. Ocampo, A. et al. (2016). In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell.

14. Sarkar, T. J. et al. (2020). Transient non-integrative expression of reprogramming factors promotes epigenetic rejuvenation. Nature Communications.

15. Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse fibroblasts. Cell.

16. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., et. al. (1998). Embryonic stem cell lines derived from human blastocysts. Science

17. Yousefzadeh, M. J. et al. (2018). Fisetin is a senolytic that extends healthspan and lifespan. EBioMedicine.

Here at Pristine’s, we care about your health. Therefore, Pristine’s recommends that you consult with your doctor before embarking on any significant alterations in your eating habits, nutritional supplement intake, or exercise routine. 

Our blogs are not able, nor intended, to substitute for professional, personalized medical advice. We ask that you discuss any points of interest raised in these blogs with a trusted medical professional.

We wish you optimal longevity and health.

Legal Disclaimer